One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
ClearPoint Neuro, Inc.
CLPT · NCM · Healthcare · Medical Devices
Current price
$9.07
52-week range
$8.27 - $28.10
Market cap
$276.67M
Balance sheet
Distressed
-10.12x Concerning
Net debt $34.58M. Interest coverage shows how many times profit covers the interest bill.
What stands out
1 Reward
2 Risks
1 rewards · 2 risks
- Reward Revenue grew 14.4% last year.
- Risk Return on equity was -226.5% last year — the company lost money on shareholders' equity.
- Risk Operating margin compressed from -79.5% to -94.2% over 3 years.
What this company does
ClearPoint Neuro, Inc.
ClearPoint Neuro makes special equipment and tools that help surgeons perform less invasive procedures in the brain. Their main income comes from selling these medical devices and related single-use items, and they also offer services to help other medical companies test and get their own products approved. This matters because it shows they are a key player in a specific and growing area of medical technology.
How the company got here
ClearPoint Neuro began in 1998 as MRI Interventions, founded by researchers at Johns Hopkins University with a vision to use MRI technology not just for diagnosis, but to guide medical procedures in real time. This groundbreaking idea aimed to enable highly precise, minimally invasive surgeries. The company officially changed its name to ClearPoint Neuro in 2020, a move that better reflected its core ClearPoint platform and signaled a broader ambition in neurosurgery and targeted drug delivery. Over the years, ClearPoint Neuro has evolved from focusing solely on navigation tools to becoming a platform company that supports the development of new therapies for the central nervous system (CNS). This evolution includes expanding into areas like biologics and drug delivery, as well as neuro laser therapy.
What it actually does
ClearPoint Neuro develops and sells medical devices and software that help surgeons perform minimally invasive procedures in the brain with great accuracy. Think of it like a highly advanced GPS system for brain surgery. Their technology guides instruments and therapies to very specific targets within the brain, which is crucial for delicate operations. They offer a range of products including hardware like head fixation frames and computer workstations, disposable tools used during surgery, and sophisticated software for planning and navigating procedures. They also provide services to help pharmaceutical companies develop and test new brain therapies.
ClearPoint Navigation Platform
This is the company's foundational business, providing the core technology for MRI-guided neurosurgery. It includes hardware, software, and disposable instruments that allow surgeons to precisely plan and execute procedures within the brain. Hospitals and neurosurgeons are the primary customers for this platform, using it for complex surgeries where pinpoint accuracy is essential. This segment is a significant part of ClearPoint Neuro's overall business, forming the basis for its other offerings.
Biologics and Drug Delivery Platform
This business line focuses on enabling the precise delivery of new therapies, such as gene and cell therapies, directly into the brain. ClearPoint Neuro provides the specialized delivery devices and support that biotechnology and pharmaceutical companies need for their central nervous system (CNS) therapy programs. These partners pay for development support and the use of ClearPoint's delivery systems, with the potential for larger commercial orders if their therapies are approved. This is a key growth area for the company, positioning it as a critical infrastructure provider for the future of brain-targeted treatments.
Prism Neuro Laser Therapy System
ClearPoint Neuro also offers a laser therapy system called Prism, which is used to treat soft tissue in the brain through a process called ablation (destroying tissue). This system adds another specialized procedure to the company's portfolio, creating opportunities for recurring revenue from disposables and services related to these treatments. This segment allows ClearPoint Neuro to address a broader range of neurological conditions and expand its offerings beyond navigation and drug delivery.
What management is betting on now
ClearPoint Neuro's management is focused on expanding its role as a platform company, particularly in the rapidly growing field of biologics and drug delivery for brain conditions. They are investing in research and development to improve their navigation accuracy and expand their delivery capabilities, aiming to become the go-to infrastructure for companies developing next-generation CNS therapies. A key strategic priority is to scale the biologics and drug delivery business, working closely with pharmaceutical partners to support their therapy development and eventual commercialization. They also aim to grow their neurosurgery navigation and laser therapy offerings, making procedures faster, simpler, and more predictable for surgeons.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-1.21M
FY2024 Q4
$-9.26M
FY2025 Q1
$-6.36M
FY2025 Q2
$-2.64M
FY2025 Q3
$-3.32M
FY2025 Q4
$-23.95M
FY2026 Q1
$-8.61M
FY2026 Q2
$-7.23M
Revenue
$10.88M
Net income
$-11.34M
Diluted EPS
-0.38
Operating cash flow
$-7.01M
Free cash flow
$-7.23M
Fetching…
Sources
Revenue
$12.13M
Net income
$-9.55M
Diluted EPS
-0.32
Operating cash flow
$-7.97M
Free cash flow
$-8.61M
Fetching…
Sources
Revenue
$10.41M
Net income
$-7.79M
Diluted EPS
-0.26
Operating cash flow
$-23.90M
Free cash flow
$-23.95M
Fetching…
Sources
Revenue
$8.86M
Net income
$-5.89M
Diluted EPS
-0.21
Operating cash flow
$-3.12M
Free cash flow
$-3.32M
Fetching…
Sources
Revenue
$9.21M
Net income
$-5.84M
Diluted EPS
-0.21
Operating cash flow
$-2.55M
Free cash flow
$-2.64M
Fetching…
Sources
Revenue
$8.48M
Net income
$-6.03M
Diluted EPS
-0.22
Operating cash flow
$-6.17M
Free cash flow
$-6.36M
Fetching…
Sources
Revenue
$7.77M
Net income
$-5.39M
Diluted EPS
-0.20
Operating cash flow
$-9.00M
Free cash flow
$-9.26M
Fetching…
Sources
Revenue
$8.12M
Net income
$-4.97M
Diluted EPS
-0.18
Operating cash flow
$-1.20M
Free cash flow
$-1.21M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $9.07
We couldn't calculate a fair value right now.
Is it drowning in debt?
Distressed
Net debt $34.6M. Interest coverage -10.1x.
Net debt
$34.58M
Interest coverage
-10.12x
ClearPoint Neuro, Inc. is healthier than 0 of 1 peers on balance-sheet leverage.
Distressed
Worse cushion
Baseline
Better cushion
CLPT
BASELINE
ClearPoint Neuro, Inc.
Total debt $63.95M Interest coverage -10.12x This is the baseline the peer rows are being compared against.
What you should know
The case for and against CLPT
1 Reward
2 Risks
Rewards
-
Revenue grew 14.4% last year.
Risks
-
Return on equity was -226.5% last year — the company lost money on shareholders' equity.
-
Operating margin compressed from -79.5% to -94.2% over 3 years.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-7.59x
P/B
25.69x
P/S
6.54x
EV/EBITDA
-11.03x
PEG ratio
0.61x
Profitability
How much profit each dollar creates
Gross margin
62.6%
Operating margin
-94.2%
Net margin
-81.8%
ROE
-226.5%
ROA
-24.4%
Health
Liquidity and balance-sheet strength
Debt / equity
5.93x
Current ratio
4.75x
Quick ratio
3.75x
Total debt
$63.95M
Total cash
$29.36M
Growth
How the business has been compounding
Revenue TTM
$42.28M
Revenue 5Y CAGR
22.7%
EPS TTM
-1.18
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-42.00M
Free CF TTM
$-24.45M
FCF margin
-57.8%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—